Japanese Pill Kills Flu in 24 Hours

Japan has approved a single-dose drug called Xofluza that cured the flu in an average of 24 hours in a clinical trial.

Isao Teshirogi, CEO of Shionogi & Co. / Image: Kiyoshi Ota/Bloomberg
Isao Teshirogi, CEO of Shionogi & Co. / Image: Kiyoshi Ota/Bloomberg

This has been one of the worst years in history for influenza in the United States, but a recent Wall Street Journal article says there’s hope in a new pill that claims to cure the flu in just one day. The drug is called Xofluza, and it was developed by Japanese pharma company Shionogi. However, the drug won’t be available in the U.S. until 2019 at the earliest.

The only drug currently available in the U.S. to combat the flu is Tamiflu, but it doesn’t kill the virus. Rather, it lowers the odds a patient will experience severe complications like pneumonia. Xofluza works differently by inhibiting an enzyme the flu virus depends on to replicate, resulting in most patients being cured in 24 hours. Before it’s available in the U.S. the single-dose drug will need to pass FDA standard toxicity testing on animals, and undergo three phases of human trials to determine safety, effectiveness, dosage, and potential issues with other drugs.

Recyclable pill bottles are gaining pharmacy ground
Aluminum and paper-based prescription bottles are moving from concept to commercial reality. Here's what pharmacy and packaging leaders need to know.
Read More
Recyclable pill bottles are gaining pharmacy ground
Fresh from the show floor: pharma packaging innovations for 2026
Serialization mandates. Containment demands. Sterile barrier requirements. Our editors found the pharma packaging innovations addressing your biggest challenges at PACK EXPO Las Vegas. Get your free curated report now.
GET YOUR COPY
Fresh from the show floor: pharma packaging innovations for 2026